Alice C. Fan
Academic Appointments
- Instructor, Medicine - Oncology
Key Documents
Contact Information
-
Clinical Offices
Medical Oncology 875 Blake Wilbur Dr MC 5826 Stanford, CA 94305 Tel Work (650) 498-6000 Fax (650) 724-1231
- Academic Offices
Personal Information Tel (650) 498-6000Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Cancer> Lymphoma
- Medical Oncology
- Kidney Cancer
- Translational Medical Research
- Molecular Targeted Therapy
- Nano-proteomics
Administrative Appointments
- Member, Stanford Lymphoma Disease Management Group (2005 - present)
- Founding Advisor, Stanford Association for Multidisciplinary Medicine and Science (2008 - present)
- Co-Director, Stanford Nanopro1000 Instrument for Nano-scale protein detection (2008 - present)
- Associate Member, Stanford Cancer Institute Molecular Therapeutics Program (2008 - present)
- Clinical Mentor, Stanford Molecular Imaging Scholars Program (2010 - present)
- Research Mentor, NIH/NIDDK Short term education program for under-represented persons (2011 - 2011)
Honors and Awards
- R21: Nanoscale proteomic profiles of hypoxia pathways to develop biomarkers of renal cell carcinoma, NIH/NCI (August 2012-July 2014)
- K23 Career Development Award, NIH/NCI (July 2010-June 2015)
- TRAM Renewal Grant: Development of blood biomarkers for diagnosis and monitoring of kidney cancer, Stanford Department of Medicine (October 2012-August 2013)
- Translational Research and Applied Medicine Program (TRAM) Pilot Grant, Stanford Department of Medicine (October 2011-September 2012)
- Developmental Cancer Research Award, Stanford Cancer Institute (September 2011-August 2012)
- Special Fellow in Clinical Research, Leukemia and Lymphoma Society (July 2006-June 2009)
Professional Education
| Fellowship: | Stanford University Medical Center CA (2006) |
| Board Certification: | Medical Oncology, American Board of Internal Medicine (2004) |
| Board Certification: | Internal Medicine, American Board of Internal Medicine (2001) |
| Internship: | Brown University - School of Medicine RI (1999) |
| Medical Education: | Albany Medical Center NY (1998) |
| B.A.: | Harvard College, Biophysics (1994) |
Graduate & Fellowship Program Affiliations
Community and International Work
- Student Travel Health, Stanford Orchestra Tour Physician, Australia, New Zealand, China&suffix=
- Violinist, Stanford Hosptial Bing Music Series, Stanford Hospital&suffix=
- Founding member of non-profit organization, "Lemonaide", Stanford Cancer Center&suffix=
- Outreach Speaker, Chinese Community Clinical Trials Forum, Bay Area&suffix=
- Grand Rounds Speaker, Hualien Hospital serving aboriginal and local Taiwanese populations, Taiwan&suffix=
Scientific Focus
Current Research Interests
Dr. Fan studies how turning off oncogenes (cancer genes) can cause tumor regression in preclinical and clinical studies. Based on preclinical findings, she has initiated clinical trials studying how tyrosine kinase inhibitors impact the hypoxia pathway in kidney cancer and the use of atorvastatin for the treatment of patients with certain non-Hodgkin's lymphomas. In the laboratory, she also uses preclinical models of cancer to validate new nanotechnology strategies for tumor diagnosis and treatment. She has shown that a new nano-immunoassay (NIA) can be used to measure how well drugs work in tumor cells sampled from individual patients with leukemia, lymphoma and myelodysplastic syndrome taking novel targeted therapies (Fan et al. Nature Medicine 2009, Seetharam, Fan et al. Leukemia Research 2012, Fan et al Oncotarget 2012). She is currently expanding her translational research to include early diagnostics, therapeutic monitoring, and prediction of response to therapeutics in solid tumors such as kidney cancer and lung cancer, with the goal of helping to make personalized medicine possible.
Publications
- "Picolog," a synthetically-available bryostatin analog, inhibits growth of MYC-induced lymphoma in vivo. Oncotarget. 2012; (1): 58-66
- Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na. Leuk Res. 2012; (1): 98-103
- Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens. Nat Med. 2009; (5): 566-71
- Supramolecular stacking of doxorubicin on carbon nanotubes for in vivo cancer therapy. Angew Chem Int Ed Engl. 2009; (41): 7668-72
- A quantitative PCR method to detect blood microRNAs associated with tumorigenesis in transgenic mice. Mol Cancer. 2008: 74
- Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas. PLoS One. 2008; (5): e2125
Help
Trial Administration